As Cytomegalovirus (CMV) infection continues to rise globally and contributes to comorbidities such as diabetes, cardiovascular disease, and certain cancers, the need for safer and more effective treatments is growing. DelveInsight reports that over 15 pharmaceutical and biotech companies are actively advancing more than 20 therapeutic candidates targeting CMV infection. These candidates are in various stages of clinical and preclinical development, highlighting significant innovation and dedication to tackling this critical public health challenge.
The “Cytomegalovirus (CMV) Infection Pipeline Insight 2025” report from DelveInsight offers a comprehensive and strategic review of the current R&D landscape. It examines clinical trial progress, emerging therapies, mechanisms of action, competitive positioning, and major company initiatives. This report is an essential resource for researchers, healthcare investors, and decision-makers seeking insights into the evolving CMV therapeutics market and the breakthroughs shaping its future.
Explore the Cutting-Edge Landscape of Cytomegalovirus (CMV) Infection Drug Development @ https://www.delveinsight.com/report-store/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Key Takeaways from the Cytomegalovirus (CMV) Infection Pipeline Report
-
DelveInsight’s report on the Cytomegalovirus (CMV) infection pipeline highlights a dynamic landscape, with over 15 active companies developing more than 20 therapeutic candidates for CMV treatment.
-
Prevymis (Letermovir) is an approved therapy for preventing Human Cytomegalovirus (HCMV) infection in transplant recipients, having received FDA approval in November 2017 and EMA marketing authorization in January 2018.
-
Leading companies, including ModernaTX, Helocyte, VBI Vaccines, SpyBiotech, Vir Biotechnology, GlaxoSmithKline, EVAXION BIOTECH, and others, are actively exploring novel therapies to enhance the CMV treatment landscape. Notable pipeline candidates in various stages of development include mRNA-1647, the Triplex CMV vaccine, VBI-1501, and several others.
Cytomegalovirus (CMV) Infection Overview:
Cytomegalovirus (CMV) is a common member of the herpesvirus family that usually causes asymptomatic or unnoticed infections in healthy individuals. However, in immunocompromised people, CMV can lead to serious health issues, including congenital infections, which may result in long-term complications such as hearing loss or developmental delays. Infection rates vary worldwide, and CMV is particularly adept at evading the immune system.
Following an initial infection, CMV enters a latent state within myeloid cells, remaining dormant for the host’s lifetime. Although typically inactive, the virus can reactivate, posing significant risks for vulnerable populations. The immune system—especially cytotoxic T-cells—plays a key role in keeping CMV suppressed. When immunity is compromised due to factors like HIV, organ transplantation, or immunosuppressive therapy, the virus can reactivate, releasing new viral particles into the bloodstream and other body fluids, causing symptoms that range from mild to severe.
Complicating its management further, CMV has been linked to certain cancers, including mucoepidermoid carcinoma and potentially prostate cancer. Its ability to remain latent and reactivate under favorable conditions makes CMV particularly challenging to control and treat.
Download the Cytomegalovirus (CMV) Infection sample report to know in detail about the Cytomegalovirus (CMV) Infection treatment market
Cytomegalovirus (CMV) Infection Pipeline Analysis
The Cytomegalovirus (CMV) Infection pipeline insights report 2025, provides insights into:
-
Provides comprehensive insights into key companies developing therapies in the Cytomegalovirus (CMV) Infection Market.
-
Categorizes Cytomegalovirus (CMV) Infection therapeutic companies by development stage: early, mid, and late-stage.
-
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
-
Reviews emerging Cytomegalovirus (CMV) Infection drugs under development based on:
-
Stage of development
-
Cytomegalovirus (CMV) Infection Route of administration
-
Target receptor
-
Monotherapy vs. combination therapy
-
Cytomegalovirus (CMV) Infection Mechanism of action
-
Molecular type
-
-
Offers detailed analysis of:
-
Company-to-company and company-academia collaborations
-
Cytomegalovirus (CMV) Infection Licensing agreements
-
Funding and investment activities supporting future Cytomegalovirus (CMV) Infection market advancement.
-
Unlock key insights into emerging Cytomegalovirus (CMV) Infection therapies and market strategies here: https://www.delveinsight.com/report-store/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Cytomegalovirus (CMV) Infection Emerging Drugs
-
mRNA-1647: ModernaTX, Inc.
mRNA-1647 is a vaccine candidate designed to protect against Cytomegalovirus (CMV) by using six distinct messenger RNAs that encode two major viral antigens. Five of these mRNAs produce the individual components of the CMV pentameric complex, while the sixth encodes Glycoprotein B (gB)—both of which are highly immunogenic. The pentameric complex allows CMV to enter various cell types, particularly epithelial cells, whereas gB enables the virus to infect a wider range of cells, including fibroblasts.
-
Cytomegalovirus vaccine (Triplex) : Helocyte
Triplex, developed by Helocyte, is a multi-antigen vaccine engineered to elicit a robust and durable T-cell response against Cytomegalovirus (CMV), especially in patients undergoing allogeneic hematopoietic stem cell transplants (HSCT) or solid organ transplants (SOT). The vaccine employs a Modified Vaccinia Ankara (MVA) viral vector to deliver three key CMV antigens—UL83 (pp65), UL123 (IE1), and UL122 (IE2)—all of which are highly immunodominant.
Cytomegalovirus (CMV) Infection Pipeline Therapeutic Assessment
Cytomegalovirus (CMV) Infection Assessment by Product Type
• Mono
• Combination
• Mono/Combination
Cytomegalovirus (CMV) Infection By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Cytomegalovirus (CMV) Infection Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Cytomegalovirus (CMV) Infection Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Download sample pages to get an in-depth assessment of the emerging Cytomegalovirus (CMV) Infection therapies and key Cytomegalovirus (CMV) Infection companies
Table of Contents
1. Report Introduction
2. Executive Summary
3. Cytomegalovirus (CMV) Infection Current Treatment Patterns
4. Cytomegalovirus (CMV) Infection – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Cytomegalovirus (CMV) Infection Late-Stage Products (Phase-III)
7. Cytomegalovirus (CMV) Infection Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Cytomegalovirus (CMV) Infection Discontinued Products
13. Cytomegalovirus (CMV) Infection Product Profiles
14. Cytomegalovirus (CMV) Infection Key Companies
15. Cytomegalovirus (CMV) Infection Key Products
16. Dormant and Discontinued Products
17. Cytomegalovirus (CMV) Infection Unmet Needs
18. Cytomegalovirus (CMV) Infection Future Perspectives
19. Cytomegalovirus (CMV) Infection Analyst Review
20. Appendix
21. Report Methodology
Request the sample PDF to get detailed insights about the Cytomegalovirus (CMV) Infection pipeline reports offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/